Anaïs Corma-Gómez

La Comisión Europea autoriza Yeytuo® Lenacapavir Gilead Sciences anuncia que la Comisión Europea CE ha concedido la autorización de comercialización para Yeytuo® lenacapavir un inhibidor de la cápside

🙌🏼More flexible PrEP regimens may improve access and adherence, particularly crucial for reaching underserved or hard-to-reach populations in HIV prevention efforts.

www.immedicohospitalario.es/noticia/5250...

🔥News: Expansion of long-acting injectable PrEP options in Europe

The European Commission has authorized Yeytuo® (lenacapavir), a twice-yearly injectable PrEP, for adults and adolescents (≥35 kg) at increased HIV‑1 risk across the EU‑27, Norway, Iceland, and Liechtenstein 👇🏼

🔴 Ya disponible el programa científico del Congreso Nacional de GeSIDA de 2025.

🔎 Descubre nuestros ponentes inaugurales, los contenidos de las sesiones plenarias y de las mesas clínicas y de ciencia básica.

➡️ www.congresogesida.es

#GeSIDA25

💬 Is a rollout justified with 30% efficacy?
In a context of rising resistance and no alternative vaccine candidates, this might be a reasonable public health decision.

📍The NHS will pilot this strategy in MSM with recent STI or multiple sexual partners.

#Gonorrhea #Vaccines #AMR #STIs #MenB

How the Meningitis Vaccine Might Protect Against Gonorrhea This Medical News article discusses the discovery of antigens that may explain reductions in gonococcal infections following meningococcal B vaccination.

📢 JAMA (2025)

The meningococcal B vaccine (4CMenB) shows ~30% protection against gonorrhea.

🔬 Recent data identify 2 cross-reactive antigens: PorB and LOS.
🧪 Not classically immunogenic, yet may be key for future vaccines.

jamanetwork.com/journals/jam...

Following FDA approval of lenacapavir for HIV PrEP, the IAS-USA panel has released an updated brief of its 2024 recommendations.
🔹 LEN for all populations
🔹 TAF/FTC for cisgender women

🔥These updates mark an important shift in the PrEP landscape.

#PrEP #HIV #Lenacapavir #TAF

Preexposure Prophylaxis for HIV To the Editor Following the US Food and Drug Administration approval of lenacapavir for HIV preexposure prophylaxis (PrEP) on June 18, 2025, as well as new data on the use of tenofovir alafenamide/emt...

📢New in JAMA!

jamanetwork.com/journals/jam...

📢 BASHH has today published national clinical guidelines on the use of doxyPEP.

This makes the UK one of the first countries globally to offer formal clinical direction on this STI prevention strategy.

🔗 Read our full statement & access the guidelines: bit.ly/4475DDK

Thanks to all patients, collaborating centers, and investigators involved in this effort.

Full text here 👇🏼👇🏼
sciencedirect.com/science/articl…

@gesida-seimc.bsky.social @GEHEP @seimc.bsky.social @CIBERINFEC

These results suggest a slower fibrosis regression in PLWH, potentially translating into a persistent risk of liver-related complications, even after HCV eradication.

#HCV #HIV #HepatitisC

After propensity score matching and competing risks modeling (death as competing event), HIV co-infection was independently associated with reduced probability of LS normalization:

37% in HCV vs. 32% in HIV/HCV (p = 0.003)

Adjusted sub-HR = 0.76 (95% CI: 0.56–0.97).

🔥Just published in eClinicalMedicine!

We analyzed the impact of HIV on liver stiffness (LS) dynamics after HCV cure in a large prospective cohort of 1,138 patients with F3/F4.

Key finding: PLWH had a significantly lower probability of LS normalization (≤7.2 kPa), despite SVR.

XV Jornadas de Enf. Emergentes
acreditadas por SNS

👉2-3 junio Auditorio @combarcelona.bsky.social
Formato híbrido
Programa definitivo e inscripciones:
uitb.cat/event/xv-jorna…

@salutpublicabcn.bsky.social #ServeisClinics #lokimica #Vircell @abbottnews.bsky.social

#EnfEmerg

Thank you very much to all the participants🙏🏼

@GEHEP @Evirologia @ofidjournal.bsky.social
#HIVSky #HCVSky

Curious about long-term outcomes after DAA therapy?
This one's for you!
Share & discuss 🔁 🧠

🇪🇦 GEHEP-011

Main findings:
• ⏳ Follow-up: median 6 years
• 12%liver events (5% HCC)
• 📊 Diagnostic performance: LS had better accuracy (AUROC 0.83 vs 0.80)
• ✅ LS <14 kPa identified 52% as low risk, missing only 3 events (1.9%)
• ✅ FAST ≤0.35 identified 59% as low risk, but missed 6 events (3.3%)

FibroScan-AST Score vs Liver Stiffness for the Prediction of Liver Events After HCV Cure AbstractBackground. Liver stiffness (LS) predicts liver complication occurrence in patients with hepatitis C virus (HCV) infection after sustained virologi

📢New publication out!

🧐Can the FAST score better predict liver events after HCV cure?
We compared FAST score vs liver stiffness (LS) in 300 patients (71%PLWH)

📨Key takeaway: FAST helps, but LS alone still performs better at predicting post-SVR complications.

👇🏼👇🏼 Read more: doi.org/10.1093/ofid...

"We condemn the censoring of science!". Powerful opening words from Diane Havlir for #croi2025

"Young researchers, we have your back. Community, we are with you"

Hell yes!!!

Are you going to #CROI2025 in San Francisco?

We hope to see you at the rally to protect critical HIV research + programming: p2a.co/YS8dsxA

📢 ¡Inscripciones abiertas!

Ya puedes registrarte en la Reunión “Cuidados diversos para necesidades diversas”, 🗓️ martes 29 de abril en la Facultad de Educación UNED

Inscripción aquí 🔗 [https://www.seisida.net/reunion2025/] #CuidadosDiversos #Educación @uneduniv.bsky.social
#Seisida2025

2024 Anal Cancer Screening Guidelines: Analysis of Clinical Performance and HRA Utilization in a large Cohort of Persons with HIV

« … all triage and co-testing strategies outperformed cytology alone. »

#IDsky #HIVsky

academic.oup.com/cid/advance-...

Doxycycline Postexposure Prophylaxis and Sexually Transmitted Infection Trends This study assesses the association of citywide doxycycline postexposure prophylaxis guideline release with reported chlamydia, gonorrhea, and early syphilis cases in men who have sex with men and in ...

Decrease In California’s STIs Followed Early Real-World Adoption Of DoxyPEP

#IDSky
#STI
#PublicHealth

jamanetwork.com/journals/jam...

Men who have sex with men in Europe still vulnerable to hepatitis A and B, highlighting need for public health action and support Research analysing European survey data from 113,884 men who have sex with men (MSM) and published in Eurosurveillance indicates that while most MSM have a basic understanding of viral hepatitis, only...

Research analysing #European survey data from 113,884 men who have sex with men (MSM) indicates that

🔹 most MSM have a basic understanding of #viral #hepatitis

🔸 only 44% report having been vaccinated against both hepatitis A & B

#publichealth #sexualhealth 😷💉⚕️
www.eurekalert.org/news-release...

Early Tecovirimat Treatment for Mpox Disease Among People With HIV - PubMed Results of this cohort study support starting tecovirimat in all PWH as soon as an mpox diagnosis is suspected. Additional research is warranted to confirm these findings.

US based STOMP trial of tecovirimat (tpoxx) for clade 2 mpox fails to demonstrate efficacy benefit. Just as it did not in PALM 007 in clade 1 mpox in DRC.

There is no known treatment for mpox

Vaccination is the key control strategy and more research is needed.
pubmed.ncbi.nlm.nih.gov/38190312/

Infectious diseases is not only about the latest trials and big cohort studies.

So, here is a list of my favourite pieces that you might missed from The Lancet Infectious Diseases in 2024 that reflect on the field at large, in no specific order.

#IDSky

Doxycycline Postexposure Prophylaxis to Prevent Bacterial Sexually Transmitted Infection This JAMA Guidelines Synopsis summarizes the 2024 Centers for Disease Control and Prevention guidelines on use of doxycycline postexposure prophylaxis (doxyPEP) for bacterial sexually transmitted infe...

jamanetwork.com/journals/jam...

Three must read papers for PhD students. #scisky #PhD #science #research #academicsky

1. The importance of stupidity in scientific research

Open Access
journals.biologists.com/jcs/article/...

Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months. The drug attaches to the lattice-like capsid proteins that shield the virus’s genetic material—a mechanism that could inspire other antivirals. Lenacapavir could help end the HIV/AIDS epidemic, but that will hinge on access for those who need it most.

Science’s 2024 Breakthrough of the Year is lenacapavir, an injectable drug that demonstrated remarkable success at preventing HIV infection with one shot every 6 months.

Learn more about this year's #BOTY and other big advances in science: scim.ag/3BrCtUn

Key points:

🇪🇦 Multicenter cohort, GEHEP-011 (1,118 individuals)
60,5% PLWH
⏳Median follow-up: 76 months
⚰️Mortality rate: 1.9 (1.4–2.5) per 100 PY in patients with HCV monoinfection vs. 1.8 (1.6–2.3) per 100 PY in PLWH

Thank you very much to all the participants🙏🏼

#HIVSky #HCVSky

No Impact of Human Immunodeficiency Virus (HIV) Coinfection on Mortality in Patients With Hepatitis C Virus Infection After Sustained Virological Response In patients with chronic HCV infection, the survival of people with HIV after sustained virological response is still not well established. This study demo

📢 Happy to share our new study: In patients who live with chronic HCV infection and advanced liver fibrosis/cirrhosis, HIV coinfection does not reduce overall survival after SVR.

academic.oup.com/cid/advance-...

@GEHEP @EVirologia @cidjournal.bsky.social

Treatment of asymptomatic chlamydia and gonorrhoea drives antibiotic consumption in PrEP cohorts Excessive consumption of antimicrobials drives antimicrobial resistance (AMR).1 The frequent emergence of AMR in subpopulations of men who have sex with men (MSM), such as HIV pre-exposure prophylaxis...

Is it time to (finally) stop screening and testing of asymptomatic PreP users for NG and CT ?
"Treatment of asymptomatic chlamydia and gonorrhoea drives antibiotic consumption in PrEP cohorts"
#IDSky #HIVSky
sti.bmj.com/content/earl...